This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Legal and regulatory update
ABSTRACT: The Office of Fair Trading (OFT) has recently found Genzyme Limited guilty of abusing its dominant position in the market for the supply of drugs for the treatment of Gaucher disease in breach of the 'Chapter II prohibition' of the Competition Act 1998. Genzyme supplies a drug called Cerezyme, which until recently was the only treatment for Gaucher disease, a rare inherited genetic disorder...
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
- Management
- Policy
- Finance
- Law
- Regulation
- Bioethics
For more information, see the Journal of Commercial Biotechnology website